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adenocarcinoma.5 Expressions of thyroid transcription fac-
tor 1 and epithelial membrane antigen in round and surface
cells of SH, accompanied by negative results of round cells
for pancytokeratin, provide useful clues for the diagnosis of
SH.2 Further studies are needed to elucidate the histogenesis
and biologic behavior to aid in the diagnosis of SH. In our
case, a false frozen-section diagnosis of non–small cell
lung cancer was made because of the presence of copious
mucoid substances and nuclear atypia. Lobectomy of the
right upper lobe with radical lymph node dissection was
therefore performed. Pathologic examination of permanent
sections revealed pulmonary SH.
The characteristic computed tomographic and magnetic
resonance imaging features of SH may help with preopera-
tive diagnosis and assessment.
We are grateful to Dr Li Wing-Yin for his assistance with the
pathologic diagnosis. We also thank Dr Wen-Juei Jeng for her con-
tribution to this article.
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Brief CommunicationsLong-term remission of hepatic hydrothorax after OK-432
pleurodesis
Pei-Ying Lin, MD, Ping-Hung Kuo, MD, Chong-Jen Yu, MD, PhD, and Pan-Chyr Yang, MD, PhD, Taipei, TaiwanHepatic hydrothorax, a manifestation of end-stage liver
disease, is defined as the presence of more than 500 mL of
pleural effusion in patients with liver cirrhosis who do not
have cardiopulmonary diseases or malignancies that could
explain this effusion.1 Strauss and Boyer2 have reported
incidences of 85.4 right-sided, 12.5% left-sided, and 2% bi-
lateral hepatic hydrothoraces. The most likely cause is fluid
transfer from the abdomen to the pleural space through dia-
phragmatic defects.1 Optimal management remains unclear,
and thoracocentesis is frequently required for immediate
symptom relief. Alternative treatments, including pleurode-
sis by tube thoracostomy or video-assisted thoracoscopic
surgery (VATS), diaphragm repair, transjugular intrahepatic
portosystemic shunt, peritoneovenous shunts, or liver trans-
plantation, should be considered when frequent therapeutic
thoracocentesis is needed.1 We report here the first case of
refractory hepatic hydrothorax in which a 5-year remission
was achieved by nonsurgical OK-432 pleurodesis.
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A 78-year-old woman with hepatitis C–related Child–
Pugh class C liver cirrhosis came to our hospital with
new-onset dyspnea and bilateral lower leg pitting edema.
There was a history of refractory right-sided hepatic
hydrothorax 5 years previously that was managed with
OK-432 pleurodesis through a pigtail after failure of re-
peated minocycline pleurodesis. Surgical intervention was
refused by the patient at that time because of older age
and poor liver reserve. The patient had a 5-year symptom-
free period with a regimen of oral diuretics and sodium
restriction.
The physical examination revealed icteric sclera, right
lower lung field dullness with decreased breath sound, and
bilateral lower extremity pitting edema. The oxygen satura-
tion was 82% on room air. Results of the neurologic exam-
ination were unremarkable. The hemogram was normal,
whereas blood biochemistry studies revealed hyponatremia
(130 mmol/L), hypoalbuminemia (2.8 g/dL), and abnormal
liver function (total bilirubin 3.5 mg/dL, direct bilirubin
1.42 mg/dL, aspartate aminotransferase 58 units/L, alanine
aminotransferase 24 U/L).
Chest radiography showed a large amount of right pleural
effusion (Figure 1, A). Echocardiography revealed a good
left ventricular ejection fraction. Chest computed tomo-
graphic scan disclosed right-sided pleural effusion with right
lower lobe atelectasis, marked liver cirrhosis, esophagealrdiovascular Surgery c Volume 136, Number 5 1367
Brief CommunicationsFIGURE 1. A, Initial chest radiograph showing right-sided, massive hepatic hydrothorax. B, Chest radiographs 6 months after second successful pleurodesis
with OK-432 reveal stable and loculated pleural effusion.varices, and minimal ascites. Cytologic studies of the pleural
effusion and ascites were both negative.
Together with daily pleural effusion drainage of as much
as 1000 mL, as well as albumin and diuretic administration,
pleurodesis with 800 mg minocycline through a pigtail cath-
eter was performed three times during the 8th to 14th hospital
days but failed. Transjugular intrahepatic portosystemic
shunt or VATS pleurodesis for the intractable hydrothorax
was again refused by the patient. Pleurodesis with OK-432
10 KE was performed on the 17th hospital day, and the
amount of daily effusion decreased dramatically to less
than 30 mL without complications. The dyspnea improved
significantly, and the oxygen saturation could be maintained
above 95% on room air. The pigtail catheter was removed on
FIGURE 2. Chest ultrasonography showing loculated pleural effusion
(PE) and thickened pleura (PL, arrows) over right hemidiaphragm.1368 The Journal of Thoracic and Cardiovascular Suthe 20th hospital day, and the patient was discharged in stable
condition with a regimen of oral diuretics.
No further thoracocentesis was required for symptom
relief. Follow-up chest radiographs (Figure 1, B) 6 months
later showed a right loculated pleural effusion. Chest ultraso-
nography (Figure 2) revealed thickened pleura of up to 5 mm
over the right hemidiaphragm. The patient has remained free
of symptoms and is leading an uneventful life.
DISCUSSION
Medical treatments of salt restriction and diuretics are
mainstays of therapy for hepatic hydrothorax but have
only a temporary effect in a third of cases.2 Although perito-
neovenous shunt and transjugular intrahepatic portosyste-
mic shunt have been reported to be useful, frequently
encountered complications, such as hepatic encephalopathy
and infection, limit their clinical applications. These proce-
dures are thus better reserved as a bridge to liver transplan-
tation.1
Successful pleurodesis with tetracycline through a tube
thoracostomy for hepatic hydrothorax was first reported in
1977.2 Repair of diaphragmatic defects with sutures and
biologic glue by VATS was successfully applied for this
condition in 1996. Since then, VATS pleurodesis with or
without diaphragmatic repair has been considered the tech-
nique of choice.3 The chemical agents used included tetracy-
cline, talc, minocycline, and OK-432.2,4,5
OK-432 is an immune modulator purified from the SU
strain of Streptococcus pyogenes A3 that has been proved
effective in controlling malignant ascites and pleural
effusion.6 In Japan, it is also used in pleurodesis for
pneumothorax and chylothorax.7-8 The experience of
OK-432 pleurodesis for hepatic hydrothorax through
a tube thoracostomy is limited to a small number of Japanese
patients.9rgery c November 2008
Brief CommunicationsPrevious reports on hepatic hydrothorax have used
different definitions of successful pleurodesis. Radiologic
evidence of recurrence is frequently observed within 2
months, even after VATS pleurodesis.3,5 Our patient is the
first reported to undergo OK-432 pleurodesis that resulted
in a 5-year remission. The second pleurodesis with OK-
432 was once again successful in terms of dramatic resolu-
tion of the recurrent hepatic hydrothorax after failure of
repeated minocycline pleurodesis.
In conclusion, patients with end-stage liver cirrhosis and
refractory hepatic hydrothorax have few therapeutic options.
Our case demonstrates that OK-432 pleurodesis through
a pigtail catheter is safe and can provide an effective alterna-
tive for patients for whom surgical intervention is not
suitable.
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Postoperative renal dysfunction develops in approximately
5% to 30% of patients undergoing cardiac surgery with
cardiopulmonary bypass, is a potent predictor of poor
outcomes, and is especially prevalent among patients with
preexisting renal dysfunction.1,2 Strategies to protect kidney
function during cardiac surgery have included the use of
low-dose dopamine, fenoldopam mesylate (INN fenoldo-
pam), bicarbonate infusion, and diuretics, yet efficacy of
any treatment has been difficult to demonstrate.
Nesiritide, a recombinant form of human B-type natri-
uretic peptide, has been suggested to be renally protective
From the Gaston Memorial Hospital, Gastonia, NC,a Southeast Texas Cardiovascular,
Houston, Tex,b Duke University School of Medicine, Durham, NC,c Washington
University School of Medicine, St Louis, Mo,d and Wayne State School of Medicine,
Detroit, Mich.e
Statistical analysis and sponsorship of the NAPA trial was provided by Scios Inc,
Mountain View, Calif.
Received for publication Oct 15, 2007; accepted for publication Dec 2, 2007.
Address for reprints: Cornelius McKown Dyke, MD, Gaston Memorial Hospital, 2555
Court Dr, Suite 200, Gastonia, NC 28056.
J Thorac Cardiovasc Surg 2008;136:1369-70
0022-5223/$34.00
Copyright  2008 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2007.12.079
The Journal of Thoracic and C2. Milanez de Campos JR, Filho LO, de Campos Werebe E, Sette H Jr, Fernandez A,
Filomeno LT, et al. Thoracoscopy and talc poudrage in the management of hepatic
hydrothorax. Chest. 2000;118:13-7.
3. Assouad J, Barthes Fle P, Shaker W, Souilamas R, Riquet M. Recurrent pleural
effusion complicating liver cirrhosis. Ann Thorac Surg. 2003;75:986-9.
4. Takayama T, Kurokawa Y, Kaiwa Y, Ansai M, Chiba T, Inoue T, et al. A new
technique of thoracoscopic pleurodesis for refractory hepatic hydrothorax. Surg
Endosc. 2004;18:140-3.
5. Ferrante D, Arguedas MR, Cerfolio RJ, Collins BG, Van Leeuwen DJ. Video-
assisted thoracoscopic surgery with talc pleurodesis in the management of symp-
tomatic hepatic hydrothorax. Am J Gastroenterol. 2002;97:3172-5.
6. Luh KT, Yang PC, Kuo SH, Chang DB, Yu CJ, Lee LN. Comparison of OK-432
and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer.
A randomized trial. Cancer. 1992;69:674-9.
7. Kishi K, Homma S, Sakamoto S, Kawabata M, Tsuboi E, Narui K, et al. High ef-
ficacy of pleurodesis using OK-432 for controlling intractable pneumothorax asso-
ciated with pulmonary lymphangioleiomyomatosis. Nihon Kokyuki Gakkai Zasshi.
2003;41:704-7.
8. Nakano A, Kato M, Watanabe T, Kawai N, Ota H, Hattori T, et al. OK-432 chem-
ical pleurodesis for the treatment of persistent chylothorax. Hepatogastroenterol-
ogy. 1994;41:568-70.
9. Saito R, Rai T, Saito H, Abe K, Takahashi A, Takiguchi J, et al. Two cases of
intractable hepatic hydrothorax successfully treated with nasal CPAP. Nippon
Shokakibyo Gakkai Zasshi. 2006;103:1146-51.renal protection in patients with
on
ronson, MD,c Nader Moazami, MD,d and Robert M. Mentzer,
nd Detroit, Mich
for patients with end-stage heart failure.3 Additionally, in
the exploratory Nesiritide Administered Peri-Anesthesia
(NAPA) trial, patients with congestive heart failure undergo-
ing cardiac surgery who received nesiritide had a signifi-
cantly lower incidence of postoperative renal dysfunction.4
The goal of this post hoc evaluation of the NAPA trial was
to assess the impact of perioperative nesiritide on patients
with preexisting, non–hemodialysis dependent, moderate-
to-severe renal dysfunction.
MATERIALS AND METHODS
The design and methodology of the NAPA trial has been reported pre-
viously.4 In brief, patients with chronic left ventricular dysfunction under-
went cardiac surgery utilizing cardiopulmonary bypass. Patients were
randomly assigned to treatment with intravenous infusion of nesiritide
(0.01 mg/[kg $ min] without bolus) or placebo in addition to usual care.
Study drug infusion was initiated after induction of anesthesia and contin-
ued for 24 to 96 hours after surgery. Inotropes and vasopressor medications
were used without restriction in accordance with institutional practice. In
the NAPA trial, 303 patients were randomly assigned, of whom 272
(nesiritide n ¼ 137, placebo n ¼ 135) ultimately underwent surgery. Of
these 272 patients, 266 (nesiritide n¼ 133, placebo n¼ 133) had a baseline
serum creatinine measurement and at least one postoperative serum creati-
nine measurement, and these patients form the basis for this evaluation.
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